Nycomed Amersham Imaging
This article was originally published in The Gray Sheet
Executive Summary
Firm commences Phase I clinical trial of lung imaging agent NC100182 to document safety following investigational new drug approval. Based on "spin signal" technology, the firm "is hopeful that potential applications will include use in patients with asthma, cystic fibrosis, chronic obstructive lung disease such as emphysema and patients undergoing transplantation and lung volume reduction surgery." The technology was derived in part through the acquisition of Magnetic Imaging Technologies last year. The Phase I trial is expected to close in the fall and a Phase II trial examining the agent could begin in early 2001